DEALS: Actavis buys generic unit for $810M


Actavis buys generic unit for $810M


DEALS

WHO

WITH

WHAT

SCOOP

Actavis Group

Alpharma

Acquisition of generic drug unit

The $810M deal narrows Alpharma's focus while boosting Actavis' presence in the US generics business.

genOway

IngenKO

Acquisition of assets

IngenKo's closing set up a deal that expands genOway's work in transgenesis, taking over a number of projects in the works.

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.